Department of Laboratory Medicine, The First Hospital of Changsha, Changsha, China.
Hunan Key Laboratory of Oncotarget Gene and Clinical Laboratory, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Front Cell Infect Microbiol. 2022 Oct 21;12:962441. doi: 10.3389/fcimb.2022.962441. eCollection 2022.
Talaromycosis is an invasive endemic mycosis caused by the dimorphic fungus (, TM). It mainly affects immunodeficient patients, especially HIV-infected individuals, which causes significant morbidity and mortality. Culture-based diagnosis takes a long turnaround time with low sensitivity, leading to treatment delay. In this study, we aimed to evaluate the performance of Metagenomic Next-Generation Sequencing (mNGS) for the rapid diagnosis of talaromycosis in HIV-infected patients.
Retrospectively analysis was conducted in HIV-infected cases at Changsha First Hospital (China) from January 2021 to March 2022. Patients who underwent routine microbiological examination and mNGS testing in parallel were enrolled. The clinical final diagnosis was used as a reference standard, and cases were classified into the TM group (60 cases) and the non-TM group (148 cases). The clinical performances of mNGS were compared with culture and serum Galactomannan (GM). The mixed infections detected by mNGS were analyzed. The impact of mNGS detection on treatment was also investigated.
The sensitivity of mNGS test reached 98.3% (95% CI, 89.8-99.9), which was significantly higher than culture (66.7% [95% CI, 53.2-77.9], < 0.001) and serum GM (83.3% [95% CI, 71.0-91.2], < 0.05). The specificity of 98.6% (95% CI, 94.7-99.7) was similar to culture (100.0% [95% CI, 96.8-100.0], = 0.156), and superior to serum GM (91.9% [95% CI, 85.9-95.5], < 0.05). In bronchoalveolar lavage fluid (BALF) samples, the positive rate of mNGS was 97.6%, which was significantly higher than culture (28.6%, 0.001). mNGS has excellent performance in the identification of mixed infection in TM group patients. , and were the most common concurrent pathogens. In summary, 60.0% (36/60) patients were added or adjusted to antimicrobial therapy after mNGS test.
mNGS is a powerful technique with high specificity and sensitivity for the rapid diagnosis of talaromycosis. mNGS of BALF samples may be a good option for early identification of in HIV-infected individuals with manifestations of infection. Moreover, mNGS shows excellent performance in mixed infection, which benefits timely treatment and potential mortality reduction.
足放线病菌病是一种由二态真菌(,TM)引起的侵袭性地方性真菌感染。它主要影响免疫功能低下的患者,特别是 HIV 感染者,导致发病率和死亡率显著增加。基于培养的诊断需要很长的周转时间,且敏感性低,导致治疗延迟。在本研究中,我们旨在评估宏基因组下一代测序(mNGS)在 HIV 感染者中快速诊断足放线病菌病的性能。
回顾性分析了 2021 年 1 月至 2022 年 3 月在长沙第一医院就诊的 HIV 感染病例。纳入同时进行常规微生物检查和 mNGS 检测的患者。以临床最终诊断为参考标准,将病例分为 TM 组(60 例)和非 TM 组(148 例)。比较 mNGS 与培养和血清半乳甘露聚糖(GM)的临床性能。分析 mNGS 检测到的混合感染。还研究了 mNGS 检测对治疗的影响。
mNGS 检测的灵敏度达到 98.3%(95%CI,89.8-99.9),明显高于培养(66.7%[95%CI,53.2-77.9],<0.001)和血清 GM(83.3%[95%CI,71.0-91.2],<0.05)。98.6%(95%CI,94.7-99.7)的特异性与培养(100.0%[95%CI,96.8-100.0],=0.156)相似,优于血清 GM(91.9%[95%CI,85.9-95.5],<0.05)。在支气管肺泡灌洗液(BALF)样本中,mNGS 的阳性率为 97.6%,明显高于培养(28.6%,0.001)。mNGS 在 TM 组患者混合感染的鉴定中具有出色的性能。和是最常见的合并病原体。总之,60.0%(36/60)的患者在 mNGS 检测后添加或调整了抗菌治疗。
mNGS 是一种快速诊断足放线病菌病的特异性和敏感性高的有力技术。BALF 样本的 mNGS 可能是 HIV 感染者出现感染表现时早期识别的良好选择。此外,mNGS 在混合感染方面表现出色,有利于及时治疗和降低潜在死亡率。